IL278122B2 - Pteridinone compounds and uses thereof - Google Patents

Pteridinone compounds and uses thereof

Info

Publication number
IL278122B2
IL278122B2 IL278122A IL27812220A IL278122B2 IL 278122 B2 IL278122 B2 IL 278122B2 IL 278122 A IL278122 A IL 278122A IL 27812220 A IL27812220 A IL 27812220A IL 278122 B2 IL278122 B2 IL 278122B2
Authority
IL
Israel
Prior art keywords
compound
nitrogen
ring
sulfur
oxygen
Prior art date
Application number
IL278122A
Other languages
English (en)
Hebrew (he)
Other versions
IL278122B1 (en
IL278122A (en
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IL278122A publication Critical patent/IL278122A/en
Publication of IL278122B1 publication Critical patent/IL278122B1/en
Publication of IL278122B2 publication Critical patent/IL278122B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL278122A 2018-04-24 2019-04-23 Pteridinone compounds and uses thereof IL278122B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862661744P 2018-04-24 2018-04-24
PCT/US2019/028604 WO2019209757A1 (en) 2018-04-24 2019-04-23 Pteridinone compounds and uses thereof

Publications (3)

Publication Number Publication Date
IL278122A IL278122A (en) 2020-11-30
IL278122B1 IL278122B1 (en) 2023-09-01
IL278122B2 true IL278122B2 (en) 2024-01-01

Family

ID=66655428

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278122A IL278122B2 (en) 2018-04-24 2019-04-23 Pteridinone compounds and uses thereof

Country Status (11)

Country Link
US (3) US11059826B2 (enExample)
EP (1) EP3784669B1 (enExample)
JP (2) JP7479293B2 (enExample)
CN (1) CN112218865B (enExample)
AR (1) AR114828A1 (enExample)
AU (1) AU2019257651B2 (enExample)
CA (1) CA3097774A1 (enExample)
ES (1) ES2969982T3 (enExample)
IL (1) IL278122B2 (enExample)
TW (1) TWI884914B (enExample)
WO (1) WO2019209757A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969982T3 (es) 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
AU2020214258B2 (en) * 2019-01-29 2025-08-28 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. AKT inhibitor
AU2020368368B2 (en) * 2019-10-14 2026-03-19 The Regents Of The University Of California Broad spectrum anti-cancer compounds
US20230322767A1 (en) 2020-07-29 2023-10-12 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
CN117088878A (zh) * 2020-10-28 2023-11-21 杭州阿诺生物医药科技有限公司 一种高活性Wnt通路抑制剂化合物
TW202334157A (zh) * 2022-01-29 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Ｗｎｔ通路抑制劑化合物
TW202333697A (zh) * 2022-01-30 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 Ｗｎｔ通路抑制劑化合物
CN114436918B (zh) * 2022-02-23 2023-05-23 郑州大学 环丁-1-烯胺类化合物及其制备方法和在药物中的应用
CN117396482B (zh) * 2022-07-28 2026-02-27 杭州阿诺生物医药科技有限公司 一种Wnt通路抑制剂化合物
WO2024022365A1 (zh) * 2022-07-28 2024-02-01 杭州阿诺生物医药科技有限公司 一种Wnt通路抑制剂化合物
US20240217951A1 (en) * 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020722A1 (de) * 2001-09-04 2003-03-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2005123736A1 (de) * 2004-06-21 2005-12-29 Boehringer Ingelheim International Gmbh Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2006018182A1 (en) * 2004-08-14 2006-02-23 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
WO2006021378A1 (de) * 2004-08-25 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
US20130225593A1 (en) * 2012-02-23 2013-08-29 Boehringer Ingelheim International Gmbh Dihydropteridinones ii
WO2014127815A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones i
WO2014127816A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones ii
WO2015193229A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
CN105801582A (zh) * 2016-04-12 2016-07-27 合肥工业大学 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1536827E (pt) 2002-08-14 2009-03-20 Silence Therapeutics Ag Utilização de proteína cinase n beta
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
EP1692153A4 (en) 2003-07-03 2007-03-21 Univ Pennsylvania INHIBITION OF EXPRESSION OF SYK-KINASE
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
AU2011226830A1 (en) * 2004-08-14 2011-10-13 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CA2617589A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX2016009975A (es) * 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
ES2969982T3 (es) * 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020722A1 (de) * 2001-09-04 2003-03-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2005123736A1 (de) * 2004-06-21 2005-12-29 Boehringer Ingelheim International Gmbh Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2006018182A1 (en) * 2004-08-14 2006-02-23 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
WO2006021378A1 (de) * 2004-08-25 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
US20130225593A1 (en) * 2012-02-23 2013-08-29 Boehringer Ingelheim International Gmbh Dihydropteridinones ii
WO2014127815A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones i
WO2014127816A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones ii
WO2015193229A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
CN105801582A (zh) * 2016-04-12 2016-07-27 合肥工业大学 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI QIU ET AL,, DESIGN, SYNTHESIS AND ANTIPROLIFERATIVE ACTIVITY OF NOVEL SUBSTITUTED 2-AMINO-7,8-DIHYDROPTERIDIN-6(5H)-ONE DERIVATIVES, 29 July 2017 (2017-07-29) *
LUKE W. KOBLAN ET AL,, ASSESSMENT OF BROMODOMAIN TARGET ENGAGEMENT BY A SERIES OF BI2536 ANALOGUES WITH MINIATURIZED BET-BRET, 6 December 2016 (2016-12-06) *

Also Published As

Publication number Publication date
ES2969982T3 (es) 2024-05-23
JP2021522237A (ja) 2021-08-30
EP3784669A1 (en) 2021-03-03
US20220363685A1 (en) 2022-11-17
IL278122B1 (en) 2023-09-01
US12384790B2 (en) 2025-08-12
EP3784669B1 (en) 2023-10-25
US20230312587A1 (en) 2023-10-05
WO2019209757A1 (en) 2019-10-31
JP7479293B2 (ja) 2024-05-08
JP2023116712A (ja) 2023-08-22
US11059826B2 (en) 2021-07-13
AU2019257651B2 (en) 2023-05-25
TW202010744A (zh) 2020-03-16
CN112218865A (zh) 2021-01-12
CN112218865B (zh) 2024-03-12
US11572364B2 (en) 2023-02-07
IL278122A (en) 2020-11-30
AR114828A1 (es) 2020-10-21
AU2019257651A1 (en) 2020-10-15
US20190322673A1 (en) 2019-10-24
CA3097774A1 (en) 2019-10-31
TWI884914B (zh) 2025-06-01

Similar Documents

Publication Publication Date Title
IL278122B2 (en) Pteridinone compounds and uses thereof
IL276147B2 (en) Gcn2 inhibitors and uses thereof
US11467490B2 (en) Salt, acid generator, resist composition and method for producing resist pattern
US6440975B1 (en) Amino acid derivatives, the preparation and use thereof as endothelin antagonists
US11739056B2 (en) Carboxylate, carboxylic acid generator, resist composition and method for producing resist pattern
US20230087041A1 (en) Methods for treating neurological disorders
US6670367B1 (en) Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed ETA/ETB endothelin receptor antagonists
US10597375B2 (en) Halogen-substituted heterocyclic compound
US20100278733A1 (en) Composition for diagnosis of amyloid-related disease
TWI901805B (zh) 鹽、酸產生劑、抗蝕劑組成物及抗蝕劑圖案的製造方法
RU2007116725A (ru) Диаминоалкановые ингибиторы аспарагиновой протеазы
TW202229221A (zh) 羧酸鹽、抗蝕劑組成物及抗蝕劑圖案的製造方法
WO2023051261A1 (zh) 一种亚胺类化合物及其应用
US6448248B1 (en) Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
EP2113258A1 (en) Aurone derivative-containing composition for diagnosis
EP4238960A1 (en) Amide derivative having antiviral activity
US5604178A (en) N-(substituted amino)pyrrole derivatives, and herbicidal compositions
CN1261352A (zh) 新的β－氨基和β－叠氮基羧酸衍生物、其制备及其作为内皮素受体拮抗剂的应用
US6358983B1 (en) Heterocyclically substituted α-hydroxycarboxylic acid derivatives, method for producing the same and their use as endothelin receptor antagonists
US5683964A (en) N-(substituted amino)imide derivatives, preparation process thereof, and herbicidal composition
KR930011304B1 (ko) 피리다지논 유도체와 그의 제조방법
HK40101424A (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
HK1026417A (en) Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
HK1227944B (en) Compounds for use in treating alzheimer’s disease in apoe4+/+ patients
HK1227944A1 (en) Compounds for use in treating alzheimer’s disease in apoe4+/+ patients